VANCOUVER, Jan. 13, 2017 /CNW/ - InMed Pharmaceuticals, Inc. ("InMed") (CSE: IN; OTCQB: IMLFF), today announced that Martin Bott, VP of Corporate Finance and Investment Banking at Eli Lilly & Company, has been appointed to InMed Board of Directors effective immediately. Mr. Bott brings over 28 years of senior financial and executive leadership to InMed's Board of Directors.
"Martin Bott has established a significant leadership position in financial and business expertise with one of the world's leading pharmaceutical companies. His depth of knowledge in navigating the complexities in healthcare finance and operations on a global level will be invaluable to InMed," said Eric A. Adams, President & Chief Executive Officer. "We welcome Martin to our Board and look forward to his strategic counsel as we work towards achieving our many corporate objectives."
Mr. Bott has a Bachelors of Business / Marketing (Cologne, Germany, 1985) and a Master's in International Business Studies (University of South Carolina, 1988). He joined Lilly in 1988 and has held roles of increasing responsibility at their headquarters in Indianapolis as well as affiliates in Switzerland, Germany, and the UK. Prior to his current assignment, Mr. Bott was the CFO for both the Diabetes Business and the Global Manufacturing and Quality organizations. He has been a member of the Lilly CFO Staff since December 2002.
"I am delighted to be joining InMed as a Board Member," stated Mr. Bott. "InMed is at a pivotal point in its evolution. Its broad base of assets, from the drug development pipeline to the cannabinoid biosynthesis and other enabling technologies, will require careful planning and execution. I look forward to working with the other Directors and executive team to contributing to the achievement of InMed's strategic initiatives and future growth."
InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed's proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company. For more information, visit www.inmedpharma.com
Cautionary Note Regarding Forward-Looking Information
Forward Looking Statements
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.
Additionally, there are known and unknown risk factors which could cause InMed Pharmaceuticals actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed Pharmaceuticals disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
These risks and uncertainties include, among others, the possibility that clinical trials will not be successful, or be completed, or confirm earlier clinical trial results, risks associated with obtaining funding from third parties, risks related to the timing and costs of clinical trials and the receipt of regulatory approvals.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
SOURCE InMed Pharmaceuticals Inc.
For further information: ON BEHALF OF THE BOARD Contact: InMed Pharmaceuticals Inc., Chris Bogart, SVP, Investor Relations and Corporate Strategy, T: 604.669.7207, E: [email protected]